{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:36:25Z","timestamp":1791005785971,"version":"4.1.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82070175"],"award-info":[{"award-number":["82070175"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"crossref","award":["2022JJ30830"],"award-info":[{"award-number":["2022JJ30830"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Scientific program of the Health Commission of Hunan Province","award":["20201179"],"award-info":[{"award-number":["20201179"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-023-01197-9","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T18:02:28Z","timestamp":1695837748000},"page":"4219-4235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma"],"prefix":"10.1007","volume":"23","author":[{"given":"Qingyang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqiao","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"9","key":"1197_CR1","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","volume":"129","author":"MA Lunning","year":"2017","unstructured":"Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 2017;129(9):1095\u2013102. https:\/\/doi.org\/10.1182\/blood-2016-09-692541.","journal-title":"Blood"},{"key":"1197_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-3-319-99716-2_5","volume":"176","author":"M Yabe","year":"2019","unstructured":"Yabe M, Dogan A, Horwitz SM, Moskowitz AJ. Angioimmunoblastic T-cell lymphoma. Cancer Treat Res. 2019;176:99\u2013126. https:\/\/doi.org\/10.1007\/978-3-319-99716-2_5.","journal-title":"Cancer Treat Res"},{"issue":"10","key":"1197_CR3","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","volume":"34","author":"S Chiba","year":"2020","unstructured":"Chiba S, Sakata-Yanagimoto M. Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia. 2020;34(10):2592\u2013606. https:\/\/doi.org\/10.1038\/s41375-020-0990-y.","journal-title":"Leukemia"},{"issue":"5","key":"1197_CR4","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.12998\/wjcc.v11.i5.1086","volume":"11","author":"M Jiang","year":"2023","unstructured":"Jiang M, Wan JH, Tu Y, et al. Angioimmunoblastic T-cell lymphoma induced hemophagocytic lymphohistiocytosis and disseminated intravascular coagulopathy: a case report. World J Clin Cases. 2023;11(5):1086\u201393. https:\/\/doi.org\/10.12998\/wjcc.v11.i5.1086.","journal-title":"World J Clin Cases"},{"issue":"11","key":"1197_CR5","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"L de Leval","year":"2007","unstructured":"de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952\u201363. https:\/\/doi.org\/10.1182\/blood-2006-10-055145.","journal-title":"Blood"},{"key":"1197_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.humpath.2022.12.003","volume":"131","author":"JH Paik","year":"2023","unstructured":"Paik JH, Koh J, Han B, et al. Distinct and overlapping features of nodal peripheral T-cell lymphomas exhibiting a follicular helper T-cell phenotype: a multicenter study emphasizing the clinicopathological significance of follicular helper T-cell marker expression. Hum Pathol. 2023;131:47\u201360. https:\/\/doi.org\/10.1016\/j.humpath.2022.12.003.","journal-title":"Hum Pathol"},{"issue":"1","key":"1197_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pathol.2019.09.012","volume":"52","author":"L de Leval","year":"2020","unstructured":"de Leval L. Approach to nodal-based T-cell lymphomas. Pathology. 2020;52(1):78\u201399. https:\/\/doi.org\/10.1016\/j.pathol.2019.09.012.","journal-title":"Pathology"},{"issue":"4","key":"1197_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.2353\/jmoldx.2006.060016","volume":"8","author":"BT Tan","year":"2006","unstructured":"Tan BT, Warnke RA, Arber DA. The frequency of B- and T-cell gene rearrangements and Epstein-Barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn. 2006;8(4):466\u201375. https:\/\/doi.org\/10.2353\/jmoldx.2006.060016. (quiz 527).","journal-title":"J Mol Diagn"},{"issue":"3","key":"1197_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1309\/6utx-gvc0-12nd-jjeu","volume":"117","author":"A Zettl","year":"2002","unstructured":"Zettl A, Lee SS, R\u00fcdiger T, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol. 2002;117(3):368\u201379. https:\/\/doi.org\/10.1309\/6utx-gvc0-12nd-jjeu.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"1197_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ajcp\/aqab090","volume":"156","author":"Y Xie","year":"2021","unstructured":"Xie Y, Jaffe ES. How I diagnose angioimmunoblastic T-cell lymphoma. Am J Clin Pathol. 2021;156(1):1\u201314. https:\/\/doi.org\/10.1093\/ajcp\/aqab090.","journal-title":"Am J Clin Pathol"},{"key":"1197_CR11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015653","author":"A Jaeger","year":"2023","unstructured":"Jaeger A, Gambheer SMM, Sun X, et al. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood. 2023. https:\/\/doi.org\/10.1182\/blood.2022015653.","journal-title":"Blood"},{"issue":"4","key":"1197_CR12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.it.2021.02.002","volume":"42","author":"J Choi","year":"2021","unstructured":"Choi J, Crotty S. Bcl6-mediated transcriptional regulation of follicular helper T cells (T(FH)). Trends Immunol. 2021;42(4):336\u201349. https:\/\/doi.org\/10.1016\/j.it.2021.02.002.","journal-title":"Trends Immunol"},{"issue":"4","key":"1197_CR13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.immuni.2016.09.018","volume":"45","author":"AP Meli","year":"2016","unstructured":"Meli AP, Font\u00e9s G, Avery DT, et al. The integrin LFA-1 controls T follicular helper cell generation and maintenance. Immunity. 2016;45(4):831\u201346. https:\/\/doi.org\/10.1016\/j.immuni.2016.09.018.","journal-title":"Immunity"},{"issue":"7533","key":"1197_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature13803","volume":"517","author":"D Liu","year":"2015","unstructured":"Liu D, Xu H, Shih C, et al. T-B-cell entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction. Nature. 2015;517(7533):214\u20138. https:\/\/doi.org\/10.1038\/nature13803.","journal-title":"Nature"},{"issue":"4","key":"1197_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/path.4920","volume":"242","author":"F Lemonnier","year":"2017","unstructured":"Lemonnier F, Mak TW. Angioimmunoblastic T-cell lymphoma: more than a disease of T follicular helper cells. J Pathol. 2017;242(4):387\u201390. https:\/\/doi.org\/10.1002\/path.4920.","journal-title":"J Pathol"},{"issue":"5","key":"1197_CR16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/cco.0000000000000773","volume":"33","author":"G Tari","year":"2021","unstructured":"Tari G, Lemonnier F, Morschhauser F. Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment. Curr Opin Oncol. 2021;33(5):400\u20135. https:\/\/doi.org\/10.1097\/cco.0000000000000773.","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"1197_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.08003.x","volume":"148","author":"L de Leval","year":"2010","unstructured":"de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br J Haematol. 2010;148(5):673\u201389. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.08003.x.","journal-title":"Br J Haematol"},{"issue":"5","key":"1197_CR18","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1182\/bloodadvances.2019001114","volume":"4","author":"M Witalis","year":"2020","unstructured":"Witalis M, Chang J, Zhong MC, et al. Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk. Blood Adv. 2020;4(5):868\u201379. https:\/\/doi.org\/10.1182\/bloodadvances.2019001114.","journal-title":"Blood Adv"},{"issue":"9","key":"1197_CR19","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","volume":"100","author":"L de Leval","year":"2015","unstructured":"de Leval L, Parrens M, Le Bras F, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica. 2015;100(9):e361\u20134. https:\/\/doi.org\/10.3324\/haematol.2015.126300.","journal-title":"Haematologica"},{"issue":"3","key":"1197_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1053\/j.semdp.2011.03.003","volume":"28","author":"P Gaulard","year":"2011","unstructured":"Gaulard P, de Leval L. Follicular helper T cells: implications in neoplastic hematopathology. Semin Diagn Pathol. 2011;28(3):202\u201313. https:\/\/doi.org\/10.1053\/j.semdp.2011.03.003.","journal-title":"Semin Diagn Pathol"},{"issue":"18","key":"1197_CR21","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1182\/blood.2022015451","volume":"140","author":"M Fujisawa","year":"2022","unstructured":"Fujisawa M, Nguyen TB, Abe Y, et al. Clonal germinal center B cells function as a niche for T-cell lymphoma. Blood. 2022;140(18):1937\u201350. https:\/\/doi.org\/10.1182\/blood.2022015451.","journal-title":"Blood"},{"issue":"3","key":"1197_CR22","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12185-013-1411-z","volume":"98","author":"H Nagoshi","year":"2013","unstructured":"Nagoshi H, Kuroda J, Kobayashi T, et al. Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis. Int J Hematol. 2013;98(3):366\u201374. https:\/\/doi.org\/10.1007\/s12185-013-1411-z.","journal-title":"Int J Hematol"},{"issue":"12","key":"1197_CR23","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1158\/2159-8290.Cd-18-0657","volume":"8","author":"PM Dominguez","year":"2018","unstructured":"Dominguez PM, Ghamlouch H, Rosikiewicz W, et al. TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes B-cell lymphomagenesis. Cancer Discov. 2018;8(12):1632\u201353. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0657.","journal-title":"Cancer Discov"},{"issue":"2","key":"1197_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1701719.","journal-title":"N Engl J Med"},{"issue":"3","key":"1197_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/path.5376","volume":"250","author":"WQ Yao","year":"2020","unstructured":"Yao WQ, Wu F, Zhang W, et al. Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. J Pathol. 2020;250(3):346\u201357. https:\/\/doi.org\/10.1002\/path.5376.","journal-title":"J Pathol"},{"issue":"2","key":"1197_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","volume":"5","author":"F Lemonnier","year":"2021","unstructured":"Lemonnier F, Safar V, Beldi-Ferchiou A, et al. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Adv. 2021;5(2):539\u201348. https:\/\/doi.org\/10.1182\/bloodadvances.2020003081.","journal-title":"Blood Adv"},{"issue":"8","key":"1197_CR27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s41379-019-0254-4","volume":"32","author":"J Steinhilber","year":"2019","unstructured":"Steinhilber J, Mederake M, Bonzheim I, et al. The pathological features of angioimmunoblastic T-cell lymphomas with IDH2(R172) mutations. Mod Pathol. 2019;32(8):1123\u201334. https:\/\/doi.org\/10.1038\/s41379-019-0254-4.","journal-title":"Mod Pathol"},{"issue":"2","key":"1197_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ccell.2023.01.003","volume":"41","author":"J Leca","year":"2023","unstructured":"Leca J, Lemonnier F, Meydan C, et al. IDH2 and TET2 mutations synergize to modulate T follicular helper cell functional interaction with the AITL microenvironment. Cancer Cell. 2023;41(2):323-39.e10. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.003.","journal-title":"Cancer Cell"},{"issue":"1","key":"1197_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41375-021-01321-2","volume":"36","author":"JC Pritchett","year":"2022","unstructured":"Pritchett JC, Yang ZZ, Kim HJ, et al. High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL). Leukemia. 2022;36(1):165\u201376. https:\/\/doi.org\/10.1038\/s41375-021-01321-2.","journal-title":"Leukemia"},{"key":"1197_CR30","doi-asserted-by":"publisher","first-page":"987227","DOI":"10.3389\/fimmu.2022.987227","volume":"13","author":"Z Chen","year":"2022","unstructured":"Chen Z, Zhu Q, Deng X, et al. Angioimmunoblastic T-cell lymphoma with predominant CD8+ tumor-infiltrating T-cells is a distinct immune pattern with an immunosuppressive microenvironment. Front Immunol. 2022;13:987227. https:\/\/doi.org\/10.3389\/fimmu.2022.987227.","journal-title":"Front Immunol"},{"issue":"9","key":"1197_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.31083\/j.fbl2709270","volume":"27","author":"J Du","year":"2022","unstructured":"Du J, Qiu C, Li WS, et al. Spatial transcriptomics analysis reveals that CCL17 and CCL22 are robust indicators of a suppressive immune environment in angioimmunoblastic T cell lymphoma (AITL). Front Biosci (Landmark Ed). 2022;27(9):270. https:\/\/doi.org\/10.31083\/j.fbl2709270.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"2","key":"1197_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171\u20135. https:\/\/doi.org\/10.1038\/ng.2872.","journal-title":"Nat Genet"},{"issue":"4","key":"1197_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/ng.2916","volume":"46","author":"HY Yoo","year":"2014","unstructured":"Yoo HY, Sung MK, Lee SH, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(4):371\u20135. https:\/\/doi.org\/10.1038\/ng.2916.","journal-title":"Nat Genet"},{"issue":"3","key":"1197_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/pai.0000000000001105","volume":"31","author":"S Jain","year":"2023","unstructured":"Jain S, Goswami A, Lone MR, et al. Follicular helper T-cell-derived nodal lymphomas: study of histomorphologic, immunophenotypic, clinical, and RHOA G17V mutational profile. Appl Immunohistochem Mol Morphol. 2023;31(3):172\u201380. https:\/\/doi.org\/10.1097\/pai.0000000000001105.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"2","key":"1197_CR35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3324\/haematol.2020.265991","volume":"107","author":"R Dobson","year":"2022","unstructured":"Dobson R, Du PY, R\u00e1s\u00f3-Barnett L, et al. Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis. Haematologica. 2022;107(2):489\u201399. https:\/\/doi.org\/10.3324\/haematol.2020.265991.","journal-title":"Haematologica"},{"issue":"4","key":"1197_CR36","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2169\/internalmedicine.9248-22","volume":"62","author":"Y Tsuboi","year":"2023","unstructured":"Tsuboi Y, Iimura Y, Matsumura F, et al. Cardiac tamponade as a recurrence of angioimmunoblastic T-cell lymphoma with the detection of a p.Gly17Val RHOA mutation in the pericardial effusion. Intern Med. 2023;62(4):595\u2013600. https:\/\/doi.org\/10.2169\/internalmedicine.9248-22.","journal-title":"Intern Med"},{"issue":"1","key":"1197_CR37","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1038\/bcj.2016.122","volume":"7","author":"TB Nguyen","year":"2017","unstructured":"Nguyen TB, Sakata-Yanagimoto M, Asabe Y, et al. Identification of cell-type-specific mutations in nodal T-cell lymphomas. Blood Cancer J. 2017;7(1):e516. https:\/\/doi.org\/10.1038\/bcj.2016.122.","journal-title":"Blood Cancer J"},{"issue":"12","key":"1197_CR38","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.4049\/jimmunol.1400839","volume":"193","author":"S Zhang","year":"2014","unstructured":"Zhang S, Konstantinidis DG, Yang JQ, et al. Gene targeting RhoA reveals its essential role in coordinating mitochondrial function and thymocyte development. J Immunol. 2014;193(12):5973\u201382. https:\/\/doi.org\/10.4049\/jimmunol.1400839.","journal-title":"J Immunol"},{"issue":"2","key":"1197_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4161\/21541248.2014.988088","volume":"6","author":"S Chiba","year":"2015","unstructured":"Chiba S, Enami T, Ogawa S, Sakata-Yanagimoto M. G17V RHOA: genetic evidence of GTP-unbound RHOA playing a role in tumorigenesis in T cells. Small GTPases. 2015;6(2):100\u20133. https:\/\/doi.org\/10.4161\/21541248.2014.988088.","journal-title":"Small GTPases"},{"issue":"2","key":"1197_CR40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","volume":"46","author":"T Palomero","year":"2014","unstructured":"Palomero T, Couronn\u00e9 L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166\u201370. https:\/\/doi.org\/10.1038\/ng.2873.","journal-title":"Nat Genet"},{"issue":"3","key":"1197_CR41","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/leu.2017.273","volume":"32","author":"M Fujisawa","year":"2018","unstructured":"Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, et al. Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia. 2018;32(3):694\u2013702. https:\/\/doi.org\/10.1038\/leu.2017.273.","journal-title":"Leukemia"},{"key":"1197_CR42","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1126\/science.aao2933","volume":"361","author":"D DiToro","year":"2018","unstructured":"DiToro D, Winstead CJ, Pham D, et al. Differential IL-2 expression defines developmental fates of follicular versus nonfollicular helper T cells. Science. 2018;361:6407. https:\/\/doi.org\/10.1126\/science.aao2933.","journal-title":"Science"},{"issue":"2","key":"1197_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.immuni.2015.01.017","volume":"42","author":"EL Stone","year":"2015","unstructured":"Stone EL, Pepper M, Katayama CD, et al. ICOS coreceptor signaling inactivates the transcription factor FOXO1 to promote Tfh cell differentiation. Immunity. 2015;42(2):239\u201351. https:\/\/doi.org\/10.1016\/j.immuni.2015.01.017.","journal-title":"Immunity"},{"issue":"2","key":"1197_CR44","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","volume":"33","author":"JR Cortes","year":"2018","unstructured":"Cortes JR, Ambesi-Impiombato A, Couronn\u00e9 L, et al. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. Cancer Cell. 2018;33(2):259-73.e7. https:\/\/doi.org\/10.1016\/j.ccell.2018.01.001.","journal-title":"Cancer Cell"},{"issue":"2","key":"1197_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1084\/jem.20141432","volume":"212","author":"JP Weber","year":"2015","unstructured":"Weber JP, Fuhrmann F, Feist RK, et al. ICOS maintains the T follicular helper cell phenotype by down-regulating Kr\u00fcppel-like factor 2. J Exp Med. 2015;212(2):217\u201333. https:\/\/doi.org\/10.1084\/jem.20141432.","journal-title":"J Exp Med"},{"issue":"1","key":"1197_CR46","doi-asserted-by":"publisher","first-page":"2134536","DOI":"10.1080\/2162402x.2022.2134536","volume":"11","author":"F Que","year":"2022","unstructured":"Que F, Zhang L, Wang T, et al. RHOA G17V induces T follicular helper cell specification and involves angioimmunoblastic T-cell lymphoma via upregulating the expression of PON2 through an NF-\u03baB-dependent mechanism. Oncoimmunology. 2022;11(1):2134536. https:\/\/doi.org\/10.1080\/2162402x.2022.2134536.","journal-title":"Oncoimmunology"},{"issue":"7","key":"1197_CR47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clml.2021.03.002","volume":"21","author":"PN Nguyen","year":"2021","unstructured":"Nguyen PN, Tran NTB, Nguyen TPX, et al. Clinicopathological implications of RHOA mutations in angioimmunoblastic T-cell lymphoma: a meta-analysis: RHOA mutations in AITL. Clin Lymphoma Myeloma Leuk. 2021;21(7):431\u20138. https:\/\/doi.org\/10.1016\/j.clml.2021.03.002.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"1197_CR48","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","volume":"132","author":"SY Ng","year":"2018","unstructured":"Ng SY, Brown L, Stevenson K, et al. RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. Blood. 2018;132(9):935\u201347. https:\/\/doi.org\/10.1182\/blood-2017-11-818617.","journal-title":"Blood"},{"issue":"9","key":"1197_CR49","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/0008-5472.Can-19-2787","volume":"80","author":"TB Nguyen","year":"2020","unstructured":"Nguyen TB, Sakata-Yanagimoto M, Fujisawa M, et al. Dasatinib is an effective treatment for angioimmunoblastic T-cell lymphoma. Cancer Res. 2020;80(9):1875\u201384. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-2787.","journal-title":"Cancer Res"},{"issue":"9","key":"1197_CR50","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","volume":"123","author":"O Odejide","year":"2014","unstructured":"Odejide O, Weigert O, Lane AA, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123(9):1293\u20136. https:\/\/doi.org\/10.1182\/blood-2013-10-531509.","journal-title":"Blood"},{"issue":"7310","key":"1197_CR51","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nature09303","volume":"466","author":"S Ito","year":"2010","unstructured":"Ito S, D\u2019Alessio AC, Taranova OV, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010;466(7310):1129\u201333. https:\/\/doi.org\/10.1038\/nature09303.","journal-title":"Nature"},{"issue":"6","key":"1197_CR52","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrm3589","volume":"14","author":"WA Pastor","year":"2013","unstructured":"Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol. 2013;14(6):341\u201356. https:\/\/doi.org\/10.1038\/nrm3589.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"1197_CR53","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc3343","volume":"12","author":"AH Shih","year":"2012","unstructured":"Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12(9):599\u2013612. https:\/\/doi.org\/10.1038\/nrc3343.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1197_CR54","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1038\/bcj.2014.83","volume":"4","author":"H Muto","year":"2014","unstructured":"Muto H, Sakata-Yanagimoto M, Nagae G, et al. Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J. 2014;4(12):e264. https:\/\/doi.org\/10.1038\/bcj.2014.83.","journal-title":"Blood Cancer J"},{"issue":"52","key":"1197_CR55","doi-asserted-by":"publisher","first-page":"15084","DOI":"10.1073\/pnas.1617929114","volume":"113","author":"F Lemonnier","year":"2016","unstructured":"Lemonnier F, Cairns RA, Inoue S, et al. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proc Natl Acad Sci USA. 2016;113(52):15084\u20139. https:\/\/doi.org\/10.1073\/pnas.1617929114.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"1197_CR56","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","volume":"126","author":"C Wang","year":"2015","unstructured":"Wang C, McKeithan TW, Gong Q, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood. 2015;126(15):1741\u201352. https:\/\/doi.org\/10.1182\/blood-2015-05-644591.","journal-title":"Blood"},{"issue":"8","key":"1197_CR57","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","volume":"119","author":"RA Cairns","year":"2012","unstructured":"Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(8):1901\u20133. https:\/\/doi.org\/10.1182\/blood-2011-11-391748.","journal-title":"Blood"},{"issue":"15","key":"1197_CR58","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","volume":"133","author":"TB Heavican","year":"2019","unstructured":"Heavican TB, Bouska A, Yu J, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133(15):1664\u201376. https:\/\/doi.org\/10.1182\/blood-2018-09-872549.","journal-title":"Blood"},{"issue":"6","key":"1197_CR59","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/leu.2016.29","volume":"30","author":"L Scourzic","year":"2016","unstructured":"Scourzic L, Couronn\u00e9 L, Pedersen MT, et al. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia. 2016;30(6):1388\u201398. https:\/\/doi.org\/10.1038\/leu.2016.29.","journal-title":"Leukemia"},{"issue":"9","key":"1197_CR60","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ng.3610","volume":"48","author":"X Zhang","year":"2016","unstructured":"Zhang X, Su J, Jeong M, et al. DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells. Nat Genet. 2016;48(9):1014\u201323. https:\/\/doi.org\/10.1038\/ng.3610.","journal-title":"Nat Genet"},{"issue":"11","key":"1197_CR61","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","volume":"128","author":"D Vallois","year":"2016","unstructured":"Vallois D, Dobay MP, Morin RD, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. Blood. 2016;128(11):1490\u2013502. https:\/\/doi.org\/10.1182\/blood-2016-02-698977.","journal-title":"Blood"},{"issue":"9","key":"1197_CR62","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1182\/blood-2016-03-707141","volume":"128","author":"RL Boddicker","year":"2016","unstructured":"Boddicker RL, Razidlo GL, Dasari S, et al. Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood. 2016;128(9):1234\u201345. https:\/\/doi.org\/10.1182\/blood-2016-03-707141.","journal-title":"Blood"},{"issue":"6","key":"1197_CR63","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3324\/haematol.2015.139253","volume":"101","author":"HY Yoo","year":"2016","unstructured":"Yoo HY, Kim P, Kim WS, et al. Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. Haematologica. 2016;101(6):757\u201363. https:\/\/doi.org\/10.3324\/haematol.2015.139253.","journal-title":"Haematologica"},{"issue":"5","key":"1197_CR64","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/leu.2015.357","volume":"30","author":"J Rohr","year":"2016","unstructured":"Rohr J, Guo S, Huo J, et al. Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia. 2016;30(5):1062\u201370. https:\/\/doi.org\/10.1038\/leu.2015.357.","journal-title":"Leukemia"},{"issue":"12","key":"1197_CR65","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.3324\/haematol.2015.133074","volume":"100","author":"SH Lee","year":"2015","unstructured":"Lee SH, Kim JS, Kim J, et al. A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients. Haematologica. 2015;100(12):e505\u20137. https:\/\/doi.org\/10.3324\/haematol.2015.133074.","journal-title":"Haematologica"},{"issue":"1","key":"1197_CR66","doi-asserted-by":"publisher","first-page":"2015170","DOI":"10.1080\/2162402x.2021.2015170","volume":"11","author":"GJ Lee","year":"2022","unstructured":"Lee GJ, Jun Y, Jeon YK, et al. Mice transgenic for human CTLA4-CD28 fusion gene show proliferation and transformation of ATLL-like and AITL-like T cells. Oncoimmunology. 2022;11(1):2015170. https:\/\/doi.org\/10.1080\/2162402x.2021.2015170.","journal-title":"Oncoimmunology"},{"issue":"48","key":"1197_CR67","doi-asserted-by":"publisher","first-page":"7990","DOI":"10.1038\/sj.onc.1208074","volume":"23","author":"EH Palacios","year":"2004","unstructured":"Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene. 2004;23(48):7990\u20138000. https:\/\/doi.org\/10.1038\/sj.onc.1208074.","journal-title":"Oncogene"},{"issue":"3","key":"1197_CR68","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ccell.2019.07.008","volume":"36","author":"L Mondrag\u00f3n","year":"2019","unstructured":"Mondrag\u00f3n L, Mhaidly R, De Donatis GM, et al. GAPDH overexpression in the T cell lineage promotes angioimmunoblastic T cell lymphoma through an NF-\u03baB-dependent mechanism. Cancer Cell. 2019;36(3):268-87.e10. https:\/\/doi.org\/10.1016\/j.ccell.2019.07.008.","journal-title":"Cancer Cell"},{"issue":"4","key":"1197_CR69","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/cancers13040610","volume":"13","author":"N Bayda","year":"2021","unstructured":"Bayda N, Tilloy V, Chaunavel A, et al. Comprehensive Epstein-Barr virus transcriptome by RNA-sequencing in angioimmunoblastic T cell lymphoma (AITL) and other lymphomas. Cancers (Basel). 2021;13(4):610. https:\/\/doi.org\/10.3390\/cancers13040610.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1197_CR70","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/cam4.2742","volume":"9","author":"AE Eladl","year":"2020","unstructured":"Eladl AE, Shimada K, Suzuki Y, et al. EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma. Cancer Med. 2020;9(2):678\u201388. https:\/\/doi.org\/10.1002\/cam4.2742.","journal-title":"Cancer Med"},{"issue":"12","key":"1197_CR71","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.3390\/cancers14122899","volume":"14","author":"R Bahri","year":"2022","unstructured":"Bahri R, Boyer F, Halabi MA, et al. Epstein-Barr virus (EBV) is mostly latent and clonal in angioimmunoblastic T cell lymphoma (AITL). Cancers (Basel). 2022;14(12):2899. https:\/\/doi.org\/10.3390\/cancers14122899.","journal-title":"Cancers (Basel)"},{"key":"1197_CR72","doi-asserted-by":"publisher","first-page":"797028","DOI":"10.3389\/fonc.2021.797028","volume":"11","author":"TY Kim","year":"2021","unstructured":"Kim TY, Min GJ, Jeon YW, et al. Impact of Epstein-Barr virus on peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma. Front Oncol. 2021;11:797028. https:\/\/doi.org\/10.3389\/fonc.2021.797028.","journal-title":"Front Oncol"},{"issue":"4","key":"1197_CR73","doi-asserted-by":"publisher","first-page":"e1010206","DOI":"10.1371\/journal.ppat.1010206","volume":"18","author":"MF Lammoglia Cobo","year":"2022","unstructured":"Lammoglia Cobo MF, Ritter J, Gary R, et al. Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL. PLoS Pathog. 2022;18(4):e1010206. https:\/\/doi.org\/10.1371\/journal.ppat.1010206.","journal-title":"PLoS Pathog"},{"key":"1197_CR74","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.2147\/ott.S189825","volume":"12","author":"S Deng","year":"2019","unstructured":"Deng S, Lin S, Shen J, Zeng Y. Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis. Onco Targets Ther. 2019;12:2335\u201342. https:\/\/doi.org\/10.2147\/ott.S189825.","journal-title":"Onco Targets Ther"},{"issue":"18","key":"1197_CR75","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group. Blood. 2010;116(18):3418\u201325. https:\/\/doi.org\/10.1182\/blood-2010-02-270785.","journal-title":"Blood"},{"issue":"10","key":"1197_CR76","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","volume":"97","author":"MH Delfau-Larue","year":"2012","unstructured":"Delfau-Larue MH, de Leval L, Joly B, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. Haematologica. 2012;97(10):1594\u2013602. https:\/\/doi.org\/10.3324\/haematol.2011.061507.","journal-title":"Haematologica"},{"key":"1197_CR77","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2022.09.008","volume":"176","author":"FO Meeuwes","year":"2022","unstructured":"Meeuwes FO, Brink M, van der Poel MWM, et al. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis. Eur J Cancer. 2022;176:100\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2022.09.008.","journal-title":"Eur J Cancer"},{"issue":"20","key":"1197_CR78","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095\u2013100. https:\/\/doi.org\/10.1182\/blood-2013-12-542142.","journal-title":"Blood"},{"issue":"1","key":"1197_CR79","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clml.2015.11.008","volume":"16","author":"R Buckstein","year":"2016","unstructured":"Buckstein R, Fraser G, Cheung M, et al. Alemtuzumab and CHOP chemotherapy for the treatment of aggressive histology peripheral T cell lymphomas: a multi-center phase I study. Clin Lymphoma Myeloma Leuk. 2016;16(1):18-28.e4. https:\/\/doi.org\/10.1016\/j.clml.2015.11.008.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"1197_CR80","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","volume":"35","author":"GG Wulf","year":"2021","unstructured":"Wulf GG, Altmann B, Ziepert M, et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial. Leukemia. 2021;35(1):143\u201355. https:\/\/doi.org\/10.1038\/s41375-020-0838-5.","journal-title":"Leukemia"},{"issue":"17","key":"1197_CR81","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","volume":"48","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Yoon DH, Kang HJ, et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer. 2012;48(17):3223\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2012.06.003.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1197_CR82","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3109\/10428194.2013.816700","volume":"55","author":"K Ganjoo","year":"2014","unstructured":"Ganjoo K, Hong F, Horning SJ, et al. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma. 2014;55(4):768\u201372. https:\/\/doi.org\/10.3109\/10428194.2013.816700.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"1197_CR83","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/jco.21.01815","volume":"40","author":"E Bachy","year":"2022","unstructured":"Bachy E, Camus V, Thieblemont C, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). J Clin Oncol. 2022;40(3):242\u201351. https:\/\/doi.org\/10.1200\/jco.21.01815.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1197_CR84","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/jco.2014.59.2782","volume":"33","author":"OA O'Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492\u20139. https:\/\/doi.org\/10.1200\/jco.2014.59.2782.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1197_CR85","doi-asserted-by":"publisher","first-page":"841","DOI":"10.20892\/j.issn.2095-3941.2020.0413","volume":"18","author":"W Zhang","year":"2021","unstructured":"Zhang W, Su L, Liu L, et al. The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b\/2 study. Cancer Biol Med. 2021;18(3):841\u20138. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0413.","journal-title":"Cancer Biol Med"},{"key":"1197_CR86","doi-asserted-by":"publisher","first-page":"175883592092382","DOI":"10.1177\/1758835920923829","volume":"12","author":"Y Sun","year":"2020","unstructured":"Sun Y, Li L, Li X, et al. Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients. Ther Adv Med Oncol. 2020;12:1758835920923829. https:\/\/doi.org\/10.1177\/1758835920923829.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"1197_CR87","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/jco.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, R\u00fcdiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106\u201313. https:\/\/doi.org\/10.1200\/jco.2008.17.4870.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1197_CR88","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/jco.2011.40.2719","volume":"30","author":"F d'Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093\u20139. https:\/\/doi.org\/10.1200\/jco.2011.40.2719.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1197_CR89","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-020-00892-4","volume":"13","author":"AC Mamez","year":"2020","unstructured":"Mamez AC, Dupont A, Blaise D, et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC). J Hematol Oncol. 2020;13(1):56. https:\/\/doi.org\/10.1186\/s13045-020-00892-4.","journal-title":"J Hematol Oncol"},{"issue":"Supplement_1","key":"1197_CR90","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood-2019-126194","volume":"134","author":"NN Bennani","year":"2019","unstructured":"Bennani NN, Pederson LD, Atherton P, et al. A phase II study of nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma. Blood. 2019;134(Supplement_1):467. https:\/\/doi.org\/10.1182\/blood-2019-126194.","journal-title":"Blood"},{"issue":"1","key":"1197_CR91","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","volume":"14","author":"Y Shi","year":"2021","unstructured":"Shi Y, Wu J, Wang Z, et al. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). J Hematol Oncol. 2021;14(1):12. https:\/\/doi.org\/10.1186\/s13045-021-01033-1.","journal-title":"J Hematol Oncol"},{"issue":"16","key":"1197_CR92","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137(16):2161\u201370. https:\/\/doi.org\/10.1182\/blood.2020009004.","journal-title":"Blood"},{"issue":"8","key":"1197_CR93","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-\u03b4, \u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888\u201398. https:\/\/doi.org\/10.1182\/blood-2017-08-802470.","journal-title":"Blood"},{"issue":"24","key":"1197_CR94","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1182\/bloodadvances.2017010819","volume":"1","author":"YA Kim","year":"2017","unstructured":"Kim YA, Byun JM, Park K, et al. Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma. Blood Adv. 2017;1(24):2138\u201346. https:\/\/doi.org\/10.1182\/bloodadvances.2017010819.","journal-title":"Blood Adv"},{"issue":"10168","key":"1197_CR95","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(18)32984-2.","journal-title":"Lancet"},{"key":"1197_CR96","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad068","author":"JM Burke","year":"2023","unstructured":"Burke JM, Liu N, Yu KS, et al. Retrospective analysis with propensity score matching of peripheral T-cell lymphoma treated frontline with brentuximab vedotin and chemotherapy. Oncologist. 2023. https:\/\/doi.org\/10.1093\/oncolo\/oyad068.","journal-title":"Oncologist"},{"key":"1197_CR97","doi-asserted-by":"publisher","first-page":"6079633","DOI":"10.1155\/2022\/6079633","volume":"2022","author":"M Shibusawa","year":"2022","unstructured":"Shibusawa M. Bortezomib use for a critically Ill patient with angioimmunoblastic T-cell lymphoma. Case Rep Hematol. 2022;2022:6079633. https:\/\/doi.org\/10.1155\/2022\/6079633.","journal-title":"Case Rep Hematol"},{"key":"1197_CR98","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.2147\/ott.S297539","volume":"14","author":"P Hu","year":"2021","unstructured":"Hu P, Ben Y, Liu J, et al. Promising response to lenalidomide-combination therapy in a discordant lymphoma consisting of EBV-positive diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report. Onco Targets Ther. 2021;14:2489\u201395. https:\/\/doi.org\/10.2147\/ott.S297539.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"1197_CR99","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/ejh.12053","volume":"90","author":"MM Beckers","year":"2013","unstructured":"Beckers MM, Huls G. Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide. Eur J Haematol. 2013;90(2):162\u20133. https:\/\/doi.org\/10.1111\/ejh.12053.","journal-title":"Eur J Haematol"},{"issue":"1","key":"1197_CR100","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/08998280.2019.1668720","volume":"33","author":"R Sawhney","year":"2020","unstructured":"Sawhney R, Volkmer RD 2nd, Cooper B. Relapsed angioimmunoblastic T-cell lymphoma with large pericardial effusion. Proc (Bayl Univ Med Cent). 2020;33(1):62\u20134. https:\/\/doi.org\/10.1080\/08998280.2019.1668720.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"11","key":"1197_CR101","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/17474086.2019.1652590","volume":"12","author":"A Ohmoto","year":"2019","unstructured":"Ohmoto A, Fuji S. Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review. Expert Rev Hematol. 2019;12(11):975\u201381. https:\/\/doi.org\/10.1080\/17474086.2019.1652590.","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"1197_CR102","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/s2352-3026(15)00023-x","volume":"2","author":"J Dupuis","year":"2015","unstructured":"Dupuis J, Morschhauser F, Ghesqui\u00e8res H, et al. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study. Lancet Haematol. 2015;2(4):e160\u20135. https:\/\/doi.org\/10.1016\/s2352-3026(15)00023-x.","journal-title":"Lancet Haematol"},{"issue":"3","key":"1197_CR103","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1200\/jop.18.00511","volume":"15","author":"AJ Moskowitz","year":"2019","unstructured":"Moskowitz AJ. Practical treatment approach for angioimmunoblastic T-cell lymphoma. J Oncol Pract. 2019;15(3):137\u201343. https:\/\/doi.org\/10.1200\/jop.18.00511.","journal-title":"J Oncol Pract"},{"issue":"4","key":"1197_CR104","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hon.2320","volume":"35","author":"B Pro","year":"2017","unstructured":"Pro B, Horwitz SM, Prince HM, et al. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol. 2017;35(4):914\u20137. https:\/\/doi.org\/10.1002\/hon.2320.","journal-title":"Hematol Oncol"},{"key":"1197_CR105","doi-asserted-by":"publisher","first-page":"875469","DOI":"10.3389\/fonc.2022.875469","volume":"12","author":"W Guo","year":"2022","unstructured":"Guo W, Wang X, Li J, et al. Chidamide maintenance therapy following induction therapy in patients with peripheral T-cell lymphoma who are ineligible for autologous stem cell transplantation: case series from China. Front Oncol. 2022;12:875469. https:\/\/doi.org\/10.3389\/fonc.2022.875469.","journal-title":"Front Oncol"},{"key":"1197_CR106","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.1434","author":"H Cho","year":"2023","unstructured":"Cho H, Yoon DH, Shin DY, et al. Current treatment patterns and the role of upfront autologous stem cell transplantation in patients with peripheral T-cell lymphoma: a Korean nationwide, multicenter prospective registry study (CISL 1404). Cancer Res Treat. 2023. https:\/\/doi.org\/10.4143\/crt.2022.1434.","journal-title":"Cancer Res Treat"},{"issue":"10","key":"1197_CR107","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry. Blood. 2014;124(10):1570\u20137. https:\/\/doi.org\/10.1182\/blood-2014-04-573089.","journal-title":"Blood"},{"issue":"9","key":"1197_CR108","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021015114","volume":"140","author":"M Brink","year":"2022","unstructured":"Brink M, Meeuwes FO, van der Poel MWM, et al. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study. Blood. 2022;140(9):1009\u201319. https:\/\/doi.org\/10.1182\/blood.2021015114.","journal-title":"Blood"},{"issue":"9","key":"1197_CR109","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","volume":"125","author":"SI Park","year":"2019","unstructured":"Park SI, Horwitz SM, Foss FM, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;125(9):1507\u201317. https:\/\/doi.org\/10.1002\/cncr.31861.","journal-title":"Cancer"},{"issue":"3","key":"1197_CR110","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdx787","volume":"29","author":"G Fossard","year":"2018","unstructured":"Fossard G, Broussais F, Coelho I, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29(3):715\u201323. https:\/\/doi.org\/10.1093\/annonc\/mdx787.","journal-title":"Ann Oncol"},{"issue":"3","key":"1197_CR111","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1182\/bloodadvances.2021005899","volume":"6","author":"M Hamadani","year":"2022","unstructured":"Hamadani M, Ngoya M, Sureda A, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Adv. 2022;6(3):920\u201330. https:\/\/doi.org\/10.1182\/bloodadvances.2021005899.","journal-title":"Blood Adv"},{"issue":"1","key":"1197_CR112","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00428-020-02790-z","volume":"477","author":"S Kim","year":"2020","unstructured":"Kim S, Kwon D, Koh J, et al. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified. Virchows Arch. 2020;477(1):131\u201342. https:\/\/doi.org\/10.1007\/s00428-020-02790-z.","journal-title":"Virchows Arch"},{"issue":"6","key":"1197_CR113","doi-asserted-by":"publisher","first-page":"e004984","DOI":"10.1136\/jitc-2022-004984","volume":"10","author":"NN Bennani","year":"2022","unstructured":"Bennani NN, Kim HJ, Pederson LD, et al. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer. 2022;10(6):e004984. https:\/\/doi.org\/10.1136\/jitc-2022-004984.","journal-title":"J Immunother Cancer"},{"issue":"17","key":"1197_CR114","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1182\/bloodadvances.2020001966","volume":"4","author":"A Neuwelt","year":"2020","unstructured":"Neuwelt A, Al-Juhaishi T, Davila E, Haverkos B. Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas. Blood Adv. 2020;4(17):4256\u201366. https:\/\/doi.org\/10.1182\/bloodadvances.2020001966.","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"1197_CR115","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/blood-2019-132278","volume":"134","author":"SP Iyer","year":"2019","unstructured":"Iyer SP, Neelapu SS, Burns E, et al. A phase I\/II study to examine the safety and efficacy of pembrolizumab 200 mg fixed dose administered every 3 weeks (Q3W) in combination with romidepsin in relapsed or refractory peripheral T-cell lymphoma (PTCL). Blood. 2019;134(Supplement_1):1546. https:\/\/doi.org\/10.1182\/blood-2019-132278.","journal-title":"Blood"},{"issue":"17","key":"1197_CR116","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","volume":"124","author":"R Bejar","year":"2014","unstructured":"Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705\u201312. https:\/\/doi.org\/10.1182\/blood-2014-06-582809.","journal-title":"Blood"},{"issue":"6","key":"1197_CR117","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/bjh.13170","volume":"168","author":"M Cheminant","year":"2015","unstructured":"Cheminant M, Bruneau J, Kosmider O, et al. Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma. Br J Haematol. 2015;168(6):913\u20136. https:\/\/doi.org\/10.1111\/bjh.13170.","journal-title":"Br J Haematol"},{"issue":"2","key":"1197_CR118","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1097\/hs9.0000000000000187","volume":"3","author":"GP Gregory","year":"2019","unstructured":"Gregory GP, Dickinson M, Yannakou CK, et al. Rapid and durable complete remission of refractory AITL with azacitidine treatment in absence of TET2 mutation or concurrent MDS. Hemasphere. 2019;3(2):e187. https:\/\/doi.org\/10.1097\/hs9.0000000000000187.","journal-title":"Hemasphere"},{"issue":"3","key":"1197_CR119","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.18632\/oncotarget.23386","volume":"9","author":"BC Valdez","year":"2018","unstructured":"Valdez BC, Li Y, Murray D, et al. Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. Oncotarget. 2018;9(3):3908\u201321. https:\/\/doi.org\/10.18632\/oncotarget.23386.","journal-title":"Oncotarget"},{"issue":"5","key":"1197_CR120","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1158\/2159-8290.Cd-16-1034","volume":"7","author":"K Yen","year":"2017","unstructured":"Yen K, Travins J, Wang F, et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 2017;7(5):478\u201393. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-1034.","journal-title":"Cancer Discov"},{"issue":"6","key":"1197_CR121","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722\u201331. https:\/\/doi.org\/10.1182\/blood-2017-04-779405.","journal-title":"Blood"},{"key":"1197_CR122","doi-asserted-by":"publisher","first-page":"1070660","DOI":"10.3389\/fimmu.2022.1070660","volume":"13","author":"Z Wang","year":"2022","unstructured":"Wang Z, Zhou H, Xu J, Wang J, Niu T. Safety and efficacy of dual PI3K-\u03b4, \u03b3 inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: a systematic review and meta-analysis of prospective clinical trials. Front Immunol. 2022;13:1070660. https:\/\/doi.org\/10.3389\/fimmu.2022.1070660.","journal-title":"Front Immunol"},{"issue":"26","key":"1197_CR123","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2021013379","volume":"138","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Ghione P, Jacobsen E, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828\u201337. https:\/\/doi.org\/10.1182\/blood.2021013379.","journal-title":"Blood"},{"issue":"3","key":"1197_CR124","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cyto.b.21881","volume":"100","author":"H Berg","year":"2021","unstructured":"Berg H, Otteson GE, Corley H, et al. Flow cytometric evaluation of TRBC1 expression in tissue specimens and body fluids is a novel and specific method for assessment of T-cell clonality and diagnosis of T-cell neoplasms. Cytometry B Clin Cytom. 2021;100(3):361\u20139. https:\/\/doi.org\/10.1002\/cyto.b.21881.","journal-title":"Cytometry B Clin Cytom"},{"key":"1197_CR125","doi-asserted-by":"publisher","first-page":"962428","DOI":"10.3389\/fmed.2022.962428","volume":"9","author":"C Wang","year":"2022","unstructured":"Wang C, Zhu L, Liu S, et al. PD-1 combined with TRBC1 and pan-T cell antibodies for robustly monitoring angioimmunoblastic T-cell lymphoma. Front Med (Lausanne). 2022;9:962428. https:\/\/doi.org\/10.3389\/fmed.2022.962428.","journal-title":"Front Med (Lausanne)"},{"issue":"16","key":"1197_CR126","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/jco.2012.48.3883","volume":"31","author":"MA Lunning","year":"2013","unstructured":"Lunning MA, Moskowitz AJ, Horwitz S. Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve. J Clin Oncol. 2013;31(16):1922\u20137. https:\/\/doi.org\/10.1200\/jco.2012.48.3883.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1197_CR127","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/sj.bmt.1705712","volume":"40","author":"SD Smith","year":"2007","unstructured":"Smith SD, Bolwell BJ, Rybicki LA, et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant. 2007;40(3):239\u201343. https:\/\/doi.org\/10.1038\/sj.bmt.1705712.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1197_CR128","doi-asserted-by":"publisher","first-page":"131","DOI":"10.14740\/jh459w","volume":"7","author":"L Norasetthada","year":"2018","unstructured":"Norasetthada L, Tantiworawit A, Rattanathammethee T, et al. Efficacy of ESHAP regimen in transplant ineligible patients with relapsed\/refractory T-cell lymphoma. J Hematol. 2018;7(4):131\u20139. https:\/\/doi.org\/10.14740\/jh459w.","journal-title":"J Hematol"},{"issue":"1","key":"1197_CR129","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-018-0696-z","volume":"12","author":"N Epperla","year":"2019","unstructured":"Epperla N, Ahn KW, Litovich C, et al. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019;12(1):6. https:\/\/doi.org\/10.1186\/s13045-018-0696-z.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1197_CR130","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","volume":"13","author":"N Mehta","year":"2013","unstructured":"Mehta N, Maragulia JC, Moskowitz A, et al. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin Lymphoma Myeloma Leuk. 2013;13(6):664\u201370. https:\/\/doi.org\/10.1016\/j.clml.2013.07.005.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"1197_CR131","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/s41375-022-01545-w","volume":"36","author":"K Kameda","year":"2022","unstructured":"Kameda K, Kako S, Kim SW, et al. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. Leukemia. 2022;36(5):1361\u201370. https:\/\/doi.org\/10.1038\/s41375-022-01545-w.","journal-title":"Leukemia"},{"issue":"9","key":"1197_CR132","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/jco.2010.29.9024","volume":"29","author":"OA O'Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182\u20139. https:\/\/doi.org\/10.1200\/jco.2010.29.9024.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1197_CR133","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1080\/10428194.2019.1622100","volume":"60","author":"BB Park","year":"2019","unstructured":"Park BB, Kim WS, Suh C, et al. A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial). Leuk Lymphoma. 2019;60(13):3251\u20137. https:\/\/doi.org\/10.1080\/10428194.2019.1622100.","journal-title":"Leuk Lymphoma"},{"key":"1197_CR134","doi-asserted-by":"publisher","first-page":"758445","DOI":"10.3389\/fonc.2021.758445","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, Li P, Qian L. Therapeutic effect of CAOLD chemotherapy regimen on patients with relapsed\/refractory angioimmunoblastic T-cell lymphoma: a case study. Front Oncol. 2021;11:758445. https:\/\/doi.org\/10.3389\/fonc.2021.758445.","journal-title":"Front Oncol"},{"key":"1197_CR135","doi-asserted-by":"publisher","first-page":"944511","DOI":"10.3389\/fonc.2022.944511","volume":"12","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zhao H, Luo J, et al. A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma. Front Oncol. 2022;12:944511. https:\/\/doi.org\/10.3389\/fonc.2022.944511.","journal-title":"Front Oncol"},{"key":"1197_CR136","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-2955","author":"JC Chavez","year":"2023","unstructured":"Chavez JC, Foss FM, William BM, et al. Targeting the inducible T-cell costimulator (ICOS) in patients with relapsed\/refractory T-follicular helper phenotype peripheral T-cell and angioimmunoblastic T-cell lymphoma. Clin Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-2955.","journal-title":"Clin Cancer Res"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01197-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01197-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01197-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T16:19:56Z","timestamp":1702743596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01197-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":136,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1197"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01197-9","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"8 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}